EREugenii A. Rabiner

Eugenii A. Rabiner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eugenii A. Rabiner has a total of 425 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study

    by Claudio Agnorelli, Joseph Peill, Danielle L Kurtin, Orla Mallon, Gabriela Sawicka, Ekaterina Shatalina, Kate Godfrey, Robin Murphy, Kirran Ahmad, Lena K L Oestreich, et al.

    Neuroplasticity, the brain's capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [11C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprotein 2A (SV2A) density, offers the most direct in vivo measure of human synaptic density, but its relationship to complementary, more scalable neuroimaging measures of structural and functional plasticity remains uncharacterised. We combined [11C]-UCBJ PET, diffusion weighted imaging (DWI/NODDI), resting-state functional magnetic resonance imaging (rs-fMRI), and electroencephalography (EEG)-based sensory tasks (roving mismatch negativity, MMN; visual long-term potentiation, vLTP) in 18 healthy volunteers to test the relationship between synaptic terminal SV2A density and complementary structural and functional neuroplasticity measures, and whether these relationships were reproducible following pharmacological challenge with ketamine (n = 11) or N,N-dimethyltryptamine (DMT; n = 7). There were no statistically significant differences in PET-derived SV2A binding potential (BPND), DWI-derived neurite orientation dispersion (ODI) and structural weighted degree (SWD), EEG-derived MMN repetition suppression, and late-phase vLTP P2 potentiation, 1 to 8 days following DMT and ketamine exposure compared to baseline. BPND was coupled with ODI across cortical regions before and after pharmacological challenge, and this relationship was tighter within visual, attentional, and frontoparietal control brain networks. SWD showed a weaker, more spatially restricted association with BPND, primarily in regions belonging to the limbic and visual brain networks, but was not replicated post-drug. No consistent association was found between BPND and functional weighted degree (FWD), derived from rs-fMRI, at baseline or after pharmacological challenge. Frontotemporal BPND was positively associated with MMN repetition suppression (r = 0.61), and occipital BPND with late-phase vLTP P2 potentiation (r = 0.54), with the MMN-BPND association replicating after pharmacological challenge (r = 0.49). These findings link synaptic terminal SV2A density in the living human brain to neurite architecture and the capacity for short-term and Hebbian-like long-term synaptic plasticity, while dissociating these relationships from generic functional connectivity and magnitude of sensory-evoked responses. These data provide cross-modal validation for DWI- and EEG-derived measures as biological indices and surrogate measures of human synaptic plasticity.

  • Open Access

    Nonclinical characterization of ACP-204, a novel selective serotonin receptor subtype 2A receptor inverse agonist

    by Ethan S. Burstein, Roger Olsson, Niklas Skold, Karl Erik Jansen, Marc Azar, Christine Sandiego, Khanum Ridler, Eugenii A. Rabiner, Gerry Rhodes, P. Markus Dey, et al.


  • Open Access

    Associations between corticolimbic glutamatergic metabolites and functional connectivity in people at clinical high-risk for psychosis

    by Abigail Gee, Nicholas R. Livingston, Amanda Kiemes, Samuel R. Knight, Paulina B. Lukow, David J. Lythgoe, Natasha Vorontsova, Jacek Donocik, James Davies, Eugenii A. Rabiner, et al.

    Recent evidence suggests that psychosis involves glutamatergic dysfunction and altered activity/connectivity within corticolimbic circuitry. While altered relationships between corticolimbic glutamatergic metabolite levels and resting-state functional connectivity (FC) have been described in schizophrenia and first-episode psychosis (FEP), whether these disruptions are also present prior to psychosis onset remains unclear. We measured Glx (glutamate + glutamine) levels in the anterior cingulate cortex (ACC) and hippocampus with magnetic resonance spectroscopy (MRS), and resting-state FC between corticolimbic regions of interest (ACC, hippocampus, amygdala and nucleus accumbens (NAc)) in antipsychotic-naïve participants at clinical high-risk for psychosis (CHR-P, n=22), compared to healthy controls (HC, n=23) and FEP participants (n=10). Primary analyses compared corticolimbic Glx-FC interactions between CHR-P and HC groups. FEP individuals were included in secondary Glx comparisons but were excluded from FC analyses due to insufficient sample size after quality control. There was a significant interaction between group and ACC Glx for FC between the NAc and the bilateral amygdala and hippocampus (p-FDR=0.021), which was driven by a significant negative association in the CHR-P group (p-FDR=0.005). Complementary seed-to-whole-brain analyses revealed additional negative associations between ACC Glx and FC with the left middle temporal gyrus, and between hippocampal Glx and FC with the parahippocampal and temporal fusiform cortices in CHR-P individuals, which were absent in HC. FEP showed higher Glx than HC across both regions (p=0.015), but there were no significant Glx differences between CHR-P and HC. These data suggest that increased risk for psychosis is associated with altered relationships between corticolimbic connectivity and glutamatergic function.

  • Open Access

    Receptor subtype distribution from PET occupancy studies: Novel analysis of maximum occupancy images using a selective drug and a non-selective tracer

    by Su Jin Kim, Alaaddin Ibrahimy, Cristian C Constantinescu, Jocelyn Hoye, Graham E Searle, Mark Slifstein, Eugenii A Rabiner, Evan D Morris

    The Lassen plot filter (LPF) is a novel quantitative approach for generating voxel-level parametric images of half maximal effective concentration (EC 50 ) and maximum occupancy ( Occ max ) from PET brain occupancy data. We applied LPF to an occupancy study of a 5HT 6 selective antagonist, PF05212377 (SAM760) using the non-selective 5HT 6 /5HT 2A tracer, [ 11 C]GSK215083. We now introduced the occupancy derived B max ratio (ODBR) as a new parameter reflecting receptor density ratios in vivo. Ten healthy subjects underwent baseline, post-drug, and washout PET scans after single oral doses (2–60 mg). LPF-derived occupancy images were produced in the striatum, yielding Occ max values of 0.74 in the caudate and 0.87 in the putamen. The ODBR for 5HT 2A receptors was calculated from incomplete occupancy (1 − Occ max ) and binding potential ratios (ODBR = 2.88; B max caudate (5HT 2A )/ B max putamen (5HT 2A )). This result is consistent with published postmortem B max ratio (1.50–2.41). In general, our approach allows estimation when occupancy studies are performed with a selective drug and a non-selective tracer.

  • Open Access

    Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach

    by Claudio Agnorelli, Joseph Peill, Gabriela Sawicka, Danielle Kurtin, Ekaterina Shatalina, Kirran Ahmad, Matthew B Wall, Catarina Rua, Kate Godfrey, Natalie Ertl, et al.

    We investigated ketamine’s neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) measures before and 1–8 days after a single psychedelic dose of ketamine (1 mg/kg, intravenous). Eleven male participants underwent two PET/MRI scans with [ 11 C]-UCBJ (synaptic density/plasticity), 1 H-MRS (glutamate and GABA) and resting-state fMRI (intrinsic brain activity, functional connectivity), before and after ketamine. While group-level analyses showed no significant increases in PET synaptic markers, ketamine administration resulted in significantly elevated glutamate levels within the anterior cingulate cortex (ACC). Functional connectivity analyses revealed reduced coupling between the ACC and the dorsolateral prefrontal cortex (dlPFC) and increased coupling between the ACC and the amygdala in the days following ketamine administration. Our multimodal analysis revealed that participants showing an increase in [ 11 C]-UCBJ volume distribution (VT), a putative index of synaptic plasticity, showed a correlated reduction in intrinsic activity within regions belonging to the default mode network (DMN). By linking molecular, cellular and network-level changes, our results point to the DMN as a central hub where ketamine may reshape brain hierarchies in the long term, providing new directions for understanding its therapeutic mechanisms and developing targeted treatments.


  • Open Access

    Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [11C]UCB-J positron emission tomography study

    by Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, Ayla Mansur, Atheeshaan Arumuham, Martin Osugo, Tiago Reis Marques, Sameer Jauhar, Ravi Mehrotra, Maja Ranger, et al.

    Converging lines of evidence implicate synaptic loss in cognitive impairment associated with schizophrenia. However, it remains unknown whether synaptic terminal density and premorbid intellectual functioning are related in vivo, or whether there are age-related changes in them in schizophrenia. To address this, we investigated whole brain grey matter synaptic vesicle glycoprotein 2A (SV2A) levels and examined their relationship with intellectual functioning and age, in forty-three patients with schizophrenia (SCZ) and 26 healthy volunteers (HV), using [ 11 C]UCB-J positron emission tomography (PET). Whole brain grey matter [ 11 C]UCB-J distribution volume ratio (DVR) was significantly lower in the SCZ than the HV group (Cohen’s d = 0.64, p = 0.01), and negatively correlated with age in both groups (Spearman’s rho = –0.46 to –0.55), with no significant group difference in magnitude of DVR-age correlations ( z = 0.44, p = 0.66). Current (Cohen’s d = 0.73) and premorbid IQ (Cliff’s delta = 0.37) were significantly lower in the SCZ than the HV group, though DVR was not significantly associated with current or premorbid IQ in either group (including in chronic medicated and early-course unmedicated SCZ subgroups). The group differences in DVR are consistent with a global deficit in synaptic terminal density in schizophrenia, with similar age-related changes in people with schizophrenia and healthy volunteers. The lack of significant relationships between DVR and premorbid or current cognitive measures are not consistent with the hypothesis that lower levels of synaptic terminal density observed in schizophrenia underlie lower levels of intellectual functioning in the disorder.


  • Open Access

    Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study

    by Edoardo Rosario de Natale, Heather Wilson, Joji P Verghese, Eoin Mulroy, Savvas Antoniadis, Alana Terry, Francesco Cavallieri, Micol Avenali, Pasquale Nigro, Varvara Valotassiou, et al.

    Purpose: We investigated serotonergic and dopaminergic terminal integrity role in PRKN- associated Parkinsonism (PRKN-PD) using [¹¹C]DASB Positron Emission Tomography (PET) and [¹²³I]FP-CIT Single Photon Emission Computerised Tomography (SPECT). Methods: Fourteen PRKN-PD patients (mean age 49.70 ± 10.83, disease duration 10.95 ± 7.59 years, H&Y 2.0 ± 0.68), and twelve iPD patients (mean age 65.40 ± 7.48 years, disease duration 5.05 ± 4.50 years, H&Y 2.0 ± 0.93) underwent clinical assessments, 3-Tesla MRI, [ 11 C]DASB PET-CT, and [ 123 I]FP-CIT SPECT, and compared with previously acquired healthy control (HCs) data. [ 11 C]DASB distribution volume ratio (DVR) parametric images were generated and DVR-1 values, equivalent to BP ND , sampled from a priori selected regions-of-interest (ROIs) with the posterior cerebellum as reference. [ 123 I]FP-CIT images underwent reconstruction and normalization to standard space, and striatal Specific Binding Ratio (SBR) calculated from the eight hottest consecutive slices. Results: PRKN-PD patients showed 20.8% to 45.2% [ 11 C]DASB BP ND loss across several cortical and subcortical ROIs compared to HCs ( p ≤ 0.01). After adjusting for age and disease duration, no differences in [ 11 C]DASB BP ND were observed between PRKN-PD and iPD. In PRKN-PD, higher [ 11 C]DASB BP ND in the raphe, brainstem, ventral striatum, and amygdala, correlated with higher scores on the Non-Motor Symptoms Scale ( p < 0.05). Higher [ 11 C]DASB BP ND in the caudate and putamen correlated with higher scores on the Beck Depression Inventory II scale ( p < 0.05). No correlation was detected between [ 11 C]DASB BP ND and [ 123 I]FP-CIT SBR in the caudate and putamen. Conclusions: PRKN-PD is characterized by widespread serotonergic dysfunction, which is independent of dopaminergic degeneration and linked to key non-motor symptoms, particularly depression. These findings provide novel insights into the pathophysiology of PRKN-PD.

  • Open Access

    The relationship between cortical synaptic terminal density marker SV2A and glutamate early in the course of schizophrenia: a multimodal PET and MRS imaging study

    by Ellis Chika Onwordi, Thomas Whitehurst, Ekaterina Shatalina, Richard Carr, Ayla Mansur, Atheeshaan Arumuham, Martin Osugo, Tiago Reis Marques, Sameer Jauhar, Susham Gupta, et al.

    Loss of glutamatergic terminals is hypothesised to contribute to excitation-inhibition imbalance in schizophrenia, supported by evidence that the normal positive association between glutamate concentrations and synaptic terminal density is not found in patients with chronic schizophrenia. However, it is unknown whether the relationship between synaptic terminal density and glutamate levels is altered early in the course of illness. To address this, we investigated [11C]UCB-J distribution volume ratio (DVR) and glutamatergic markers in healthy volunteers (HV) and in antipsychotic-naïve/free patients with schizophrenia (SCZ) recruited from first-episode psychosis services. Forty volunteers (HV n = 19, SCZ n = 21) underwent [11C]UCB-J positron emission tomography and proton magnetic resonance spectroscopy (1H-MRS) imaging in the anterior cingulate cortex (ACC) and left hippocampus to index [11C]UCB-J DVR and creatine-scaled glutamate (Glu/Cr) and glutamate in combination with glutamine (Glx/Cr). In the HV but not SCZ group, [11C]UCB-J DVR was significantly positively associated with Glu/Cr (Spearman’s rho = 0.55, p = 0.02) and Glx/Cr (Spearman’s rho = 0.73, p = 0.0004) in the ACC, and with Glu/Cr in the left hippocampus (Spearman’s rho = 0.77, p = 0.0001). DVR was significantly lower in the ACC in the SCZ group compared to the HV group (Kolmogorov-Smirnov Z = 1.44, p = 0.03). Together, these findings indicate that the normal relationship between levels of a synaptic terminal density marker and levels of glutamate is disrupted early in the course of schizophrenia. This is consistent with the hypothesis that there is loss of glutamatergic terminals at illness onset.


  • Open Access

    Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study

    by Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, Richard Wong, Gordon Loewen, Nagdeep Giri, Heather Skor, Kelly Lin, Christine M. Sandiego, Meghan Pajonas, et al.

  • Open Access

    Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study

    by Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, Richard Wong, Gordon Loewen, Nagdeep Giri, Heather Skor, Kelly Lin, Christine M. Sandiego, Meghan Pajonas, et al.

    Positron emission tomography (PET) is frequently used to obtain target occupancy (%TO) of central nervous system (CNS) drug candidates during clinical development. Obtaining %TO with PET can be particularly powerful when the %TO associated with efficacy is known for a protein target. Using the radiotracer [18F]AV-133, the relationship between plasma concentration (PK) and %TO of NBI-750142, an experimental inhibitor of the vesicular monoamine transporter type 2 (VMAT2) was obtained in both nonhuman primate (NHP) and human. This work established [18F]AV-133 PET as capable of providing a VMAT2 inhibitor PK-%TO relationship that translated from NHP to human. To establish the VMAT2%TO benchmark, PET was performed in NHP with NBI-98782, the main active metabolite of valbenazine, and this PK-%TO relationship was used to estimate VMAT2%TO at NBI-98782 exposures associated with valbenazine therapeutic effects in the treatment of tardive dyskinesia (TD). This work defined 85–90% as the VMAT2%TO achieved by exposures associated with daily dosing with 80 mg valbenazine, a dosing regimen known to exhibit a large effect size in the treatment of TD and in the treatment of chorea associated with Huntington’s Disease. NBI-750142 was estimated to achieve 36–78% VMAT2 target occupancy at acceptable doses, indicating potential inferiority in conferring clinical benefit compared to valbenazine. It is recommended that the %TO benchmark of valbenazine derived from [18F]AV-133 PET serve as a gold standard biomarker to evaluate novel VMAT2 inhibitors undergoing clinical development.